Gordon named CEO at Gemini Bioproducts

Gemini Bioproducts LLC, a portfolio company of BelHealth Investment Partners LLC, has appointed Dale Gordon as its CEO. Gordon was previously commercial general manager at GE Healthcare Life Sciences, a unit of GE.

PRESS RELEASE

New York, New York and West Sacramento, CA – September 19, 2018 – Gemini Bioproducts, LLC (“Gemini” or the “Company”), a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, announced the appointment of Dale Gordon as Chief Executive Officer (“CEO”). Gemini was founded in 1985 by Bertram Polan, who grew the Company from the ground up to its national and international footprint today. Mr. Polan will continue with the Company as Chairman of the Board.

Dale Gordon has over 27 years of experience in the life science industry. Notably, for 24 years, Mr. Gordon held various commercial leadership roles at MilliporeSigma, a subsidiary of Merck KGaA (ETR:MRK), where he was most recently Head of Commercial Marketing in the Americas. Following his tenure at MilliporeSigma, Mr. Gordon became the Commercial General Manager at GE Healthcare Life Sciences, a unit of General Electric (NYSE: GE), where he was responsible for Account Management.

Dale Gordon stated “Over the last 33 years, Bertram has built an exceptional business at Gemini that is well positioned to thrive alongside the rapid expansion of the biotechnology and cell therapy sector, and I am excited to work with the existing team to lead the Company in the next chapter of its journey. I believe that my deep sector experience at GE and Merck will allow me to bring a differentiated perspective to Gemini. I look forward to continuing the Company’s operational excellence with a focus on high quality products and thoughtful customer service. Finally, I am thrilled to partner with BelHealth and leverage the firm’s operational focus and capital resources to continue Gemini’s growth across new products and production capabilities.”

Rebecca Yu, Vice President of BelHealth and Board Member of Gemini, added “We are delighted to welcome Dale to the Gemini leadership team. Dale’s expertise positions us well to scale Gemini into a diversified platform solution to supply the research labs in the expanding field of cell therapy. Furthermore, given his many years of leadership at Gemini, Bertram will be an insightful partner to the Board and management team in his new Chairman role.”

About Gemini Bio-Products
Founded in 1985, Gemini is a supplier of cell culture media, sera, and other reagents to many of the world’s top research and academic communities, biotechnology firms, and pharmaceutical companies. Today, Gemini operates from a 14,000 square foot manufacturing facility in West Sacramento, California. A national sales force and an international distribution network serves cell culture laboratories worldwide.
About BelHealth Investment Partners
BelHealth Investment Partners, based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes would benefit from its extensive operating and private equity investment expertise. The firm invests across three core healthcare segments: Services, Products and Distribution. BelHealth is investing from its current $350 million fund.